Counselors in Floyd, VA Accepting Medicare
9 Counselors found. Showing 1 - 9
 Taylor Kenneth Simpson Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 148 Rehoboth Ln Ne, Floyd, VA 24091 Phone: 540-745-4001 |
 Jessica Talley-haynes, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 141 Chesnut Ln Se Unit 3, Floyd, VA 24091 Phone: 540-525-1060 |
Mr. William Howell Curtis Ii, CSAC Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 148 Rehoboth Ln Ne, Floyd, VA 24091 Phone: 540-745-4001 |
Shelly Noelle Fox, MA Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 401 S Locust St, Floyd, VA 24091 Phone: 540-501-7169 Fax: 540-745-4706 |
Peter Burggraf Counselor Medicare: Not Enrolled in Medicare Practice Location: 4410 Christiansburg Pike Ne, Floyd, VA 24091 Phone: 540-745-0885 |
Amanda Buckner, LPC Counselor - Professional Medicare: Medicare Enrolled Practice Location: 260 Webbs Mill Rd N, Floyd, VA 24091 Phone: 540-745-2047 Fax: 540-322-1835 |
Ms. Patricia Scott-cobb, LPC Counselor - Professional Medicare: Medicare Enrolled Practice Location: 260 Webbs Mill Rd N, Floyd, VA 24091 Phone: 540-745-2047 Fax: 540-322-1835 |
Grant Phillip Hinson, CSAC, QMHP-A, RPRS Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 148 Rehoboth Ln Ne, Floyd, VA 24091 Phone: 540-745-4001 Fax: 540-858-1913 |
Mr. Joseph Klein, LPC Counselor - Mental Health Medicare: Medicare Enrolled Practice Location: 151 Ridge Haven Rd Se, Floyd, VA 24091 Phone: 540-239-2838 |
News Archive
Study provides detailed characterization of neurotoxicity arising from CD19 CAR T-cell therapy
New potential biomarkers and a novel algorithm could help identify patients at increased risk of suffering from severe neurotoxicity after receiving CD19 CAR T-cell therapy. The study extensively characterized common and occasionally fatal side effects of this immunotherapy.
Top-line results from Genzyme's teriflunomide and Rebif Phase III comparison trial on RMS
Genzyme, a Sanofi company, today reported top-line results from TENERE, a Phase III clinical trial comparing the effectiveness, safety and tolerability of once-daily oral teriflunomide to interferon beta-1a, an approved injectable therapy, in people with relapsing forms of multiple sclerosis.
Gingival crevicular fluid predicts periodontal attachment loss
Analysis of gingival crevicular fluid using mass spectrometry could be used to predict sites of periodontal attachment loss in individuals undergoing maintenance therapy for periodontitis, report researchers.
NanoViricides files financial year end annual report with SEC
NanoViricides, Inc. reports that it has filed its financial year end annual report (Form 10K) with the Securities and Exchange Commission (SEC) yesterday in a timely manner.
› Verified 6 days ago